on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics presents a novel antibody at the AAI Congress 2026
OSE Immunotherapeutics unveiled a novel monoclonal antibody agonist targeting the FPR2 receptor at the 2026 Annual Meeting of the American Association of Immunologists in Boston. This first-in-class antibody represents an innovative approach to resolving chronic inflammation. By activating the body's natural mechanisms, this therapy promises new perspectives for chronic inflammatory diseases, which are characterized by largely unmet medical needs. Aurore Morello, PhD, presented this innovative strategy, which could transform the management of these diseases by promoting the resolution, rather than the suppression, of inflammatory symptoms.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news